We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Researchers at Salk Institute for Biological Studies ...
Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 ...
DelveInsight's CTLA-4 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging CTLA-4 inhibitors, market share of individual therapies, and ...
Checkpoint inhibitors act as a double-edged sword against cancer. Although they promote potent antitumor responses, they can also cause several adverse effects. This article joins a growing series on ...
Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 ...
SAN FRANCISCO and SUZHOU, China, Feb. 23, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite ...
High-dose 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) chemoembolization for treatment-naïve patients with limited uveal melanoma hepatic metastases. Nautilus, a phase 1b/2 trial of combining oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results